var grades = [null,"\n\n<div class=\"graphic\">\n<div class=\"figure\">\n<div class=\"ttl\">\nGrade 1A recommendation \n</div>\n<div class=\"cntnt\">\n\n<table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">A Grade 1A recommendation is a strong recommendation, and applies to most patients in most circumstances without reservation. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Explanation:</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">A Grade 1 recommendation is a strong recommendation. It means that we believe that if you follow the recommendation, you will be doing more good than harm for most, if not all of your patients.</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Grade A means that the best estimates of the critical benefits and risks come from consistent data from well-performed, randomized, controlled trials or overwhelming data of some other form (eg, well-executed observational studies with very large treatment effects). Further research is unlikely to have an impact on our confidence in the estimates of benefit and risk.</td>\n</tr>\n\n</tbody>\n</table>\n</div>\n\n<div class=\"graphic_lgnd\"><strong>Recommendation grades</strong><br />\t\n1. Strong recommendation: Benefits clearly outweigh the risks and burdens (or vice versa) for most, if not all, patients<br />\n2. Weak recommendation: Benefits and risks closely balanced and/or uncertain<br /><br />\n<strong>Evidence grades</strong><br />\nA. High-quality evidence: Consistent evidence from randomized trials, or overwhelming evidence of some other form<br />\nB. Moderate-quality evidence: Evidence from randomized trials with important limitations, or very strong evidence of some other form<br />\nC. Low-quality evidence: Evidence from observational studies, unsystematic clinical observations, or from randomized trials with serious flaws<br /><br />\nFor a complete description of our grading system, please see the UpToDate editorial policy.</div>\n<div class=\"graphic_footnotes\"></div> \n<div class=\"graphic_reference\"></div>\n\n\n</div>\n</div>\n\n\n","\n\n<div class=\"graphic\">\n<div class=\"figure\">\n<div class=\"ttl\">\nGrade 1B recommendation \n</div>\n<div class=\"cntnt\">\n\n<table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">A Grade 1B recommendation is a strong recommendation, and applies to most patients. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Explanation:</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">A Grade 1 recommendation is a strong recommendation. It means that we believe that if you follow the recommendation, you will be doing more good than harm for most, if not all of your patients.</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Grade B means that the best estimates of the critical benefits and risks come from randomized, controlled trials with important limitations (eg, inconsistent results, methodologic flaws, imprecise results, extrapolation from a different population or setting) or very strong evidence of some other form. Further research (if performed) is likely to have an impact on our confidence in the estimates of benefit and risk, and may change the estimates.</td>\n</tr>\n\n</tbody>\n</table>\n</div>\n\n<div class=\"graphic_lgnd\"><strong>Recommendation grades</strong><br />\t\n1. Strong recommendation: Benefits clearly outweigh the risks and burdens (or vice versa) for most, if not all, patients<br />\n2. Weak recommendation: Benefits and risks closely balanced and/or uncertain<br /><br />\n<strong>Evidence grades</strong><br />\nA. High-quality evidence: Consistent evidence from randomized trials, or overwhelming evidence of some other form<br />\nB. Moderate-quality evidence: Evidence from randomized trials with important limitations, or very strong evidence of some other form<br />\nC. Low-quality evidence: Evidence from observational studies, unsystematic clinical observations, or from randomized trials with serious flaws<br /><br />\nFor a complete description of our grading system, please see the UpToDate editorial policy.</div>\n<div class=\"graphic_footnotes\"></div> \n<div class=\"graphic_reference\"></div>\n\n</div>\n</div>\n\n\n","\n\n<div class=\"graphic\">\n<div class=\"figure\">\n<div class=\"ttl\">\nGrade 1C recommendation \n</div>\n<div class=\"cntnt\">\n\n<table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">A Grade 1C recommendation is a strong recommendation; however, some of the key evidence supporting the recommendation is of low quality. While we currently believe the recommendation applies to most patients, the recommendation may change when higher quality evidence becomes available.</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Explanation:</td>\n</tr>\n\n<tr>\n<td class=\"indent1\" colspan=\"1\">A Grade 1 recommendation is a strong recommendation. It means that we believe that if you follow the recommendation, you will be doing more good than harm for most, if not all of your patients.</td>\n</tr>\n\n<tr>\n<td class=\"indent1\" colspan=\"1\">Grade C means the evidence comes from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.</td>\n</tr>\n\n</tbody>\n</table>\n</div>\n\n<div class=\"graphic_lgnd\"><strong>Recommendation grades</strong><br />\t\n1. Strong recommendation: Benefits clearly outweigh the risks and burdens (or vice versa) for most, if not all, patients<br />\n2. Weak recommendation: Benefits and risks closely balanced and/or uncertain<br /><br />\n<strong>Evidence grades</strong><br />\nA. High-quality evidence: Consistent evidence from randomized trials, or overwhelming evidence of some other form<br />\nB. Moderate-quality evidence: Evidence from randomized trials with important limitations, or very strong evidence of some other form<br />\nC. Low-quality evidence: Evidence from observational studies, unsystematic clinical observations, or from randomized trials with serious flaws<br /><br />\nFor a complete description of our grading system, please see the UpToDate editorial policy.</div>\n<div class=\"graphic_footnotes\"></div> \n<div class=\"graphic_reference\"></div>\n\n</div>\n</div>\n\n\n","\n\n<div class=\"graphic\">\n<div class=\"figure\">\n<div class=\"ttl\">\nGrade 2A recommendation \n</div>\n<div class=\"cntnt\">\n\n<table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">A Grade 2A recommendation is a weak recommendation, and the best action may differ depending on circumstances or patient or societal values.</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Explanation:</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">A Grade 2 recommendation is a weak recommendation. It means \"this is our suggestion, but you may want to think about it.\" It is unlikely that you should follow the suggested approach in all your patients, and you might reasonably choose an alternative approach. For Grade 2 recommendations, benefits and risks may be finely balanced, or the benefits and risks may be uncertain. In deciding whether to follow a Grade 2 recommendation in an individual patient, you may want to think about your patient's values and preferences or about your patient's risk aversion.</td>\n</tr>\n\n<tr>\n<td class=\"indent1\" colspan=\"1\">Grade A means that the best estimates of the critical benefits and risks come from consistent data from well-performed, randomized, controlled trials or overwhelming data of some other form (eg, well-executed observational studies with very large treatment effects). Further research is unlikely to have an impact on our confidence in the estimates of benefit and risk.</td>\n</tr>\n\n</tbody>\n</table>\n</div>\n\n<div class=\"graphic_lgnd\"><strong>Recommendation grades</strong><br />\t\n1. Strong recommendation: Benefits clearly outweigh the risks and burdens (or vice versa) for most, if not all, patients<br />\n2. Weak recommendation: Benefits and risks closely balanced and/or uncertain<br /><br />\n<strong>Evidence grades</strong><br />\nA. High-quality evidence: Consistent evidence from randomized trials, or overwhelming evidence of some other form<br />\nB. Moderate-quality evidence: Evidence from randomized trials with important limitations, or very strong evidence of some other form<br />\nC. Low-quality evidence: Evidence from observational studies, unsystematic clinical observations, or from randomized trials with serious flaws<br /><br />\nFor a complete description of our grading system, please see the UpToDate editorial policy.</div>\n<div class=\"graphic_footnotes\"></div> \n<div class=\"graphic_reference\"></div>\n\n</div>\n</div>\n\n\n","\n\n<div class=\"graphic\">\n<div class=\"figure\">\n<div class=\"ttl\">\nGrade 2B recommendation \n</div>\n<div class=\"cntnt\">\n\n<table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">A Grade 2B recommendation is a weak recommendation; alternative approaches may be better for some patients under some circumstances.</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Explanation:</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">A Grade 2 recommendation is a weak recommendation. It means \"this is our suggestion, but you may want to think about it.\" It is unlikely that you should follow the suggested approach in all your patients, and you might reasonably choose an alternative approach. For Grade 2 recommendations, benefits and risks may be finely balanced, or the benefits and risks may be uncertain. In deciding whether to follow a Grade 2 recommendation in an individual patient, you may want to think about your patient's values and preferences or about your patient's risk aversion.</td>\n</tr>\n\n<tr>\n<td class=\"indent1\" colspan=\"1\">Grade B means that the best estimates of the critical benefits and risks come from randomized, controlled trials with important limitations (eg, inconsistent results, methodologic flaws, imprecise results, extrapolation from a different population or setting) or very strong evidence of some other form. Further research (if performed) is likely to have an impact on our confidence in the estimates of benefit and risk, and may change the estimates.</td>\n</tr>\n\n</tbody>\n</table>\n</div>\n\n<div class=\"graphic_lgnd\"><strong>Recommendation grades</strong><br />\t\n1. Strong recommendation: Benefits clearly outweigh the risks and burdens (or vice versa) for most, if not all, patients<br />\n2. Weak recommendation: Benefits and risks closely balanced and/or uncertain<br /><br />\n<strong>Evidence grades</strong><br />\nA. High-quality evidence: Consistent evidence from randomized trials, or overwhelming evidence of some other form<br />\nB. Moderate-quality evidence: Evidence from randomized trials with important limitations, or very strong evidence of some other form<br />\nC. Low-quality evidence: Evidence from observational studies, unsystematic clinical observations, or from randomized trials with serious flaws<br /><br />\nFor a complete description of our grading system, please see the UpToDate editorial policy.</div>\n<div class=\"graphic_footnotes\"></div> \n<div class=\"graphic_reference\"></div>\n\n</div>\n</div>\n\n\n","\n\n<div class=\"graphic\">\n<div class=\"figure\">\n<div class=\"ttl\">\nGrade 2C recommendation \n</div>\n<div class=\"cntnt\">\n\n<table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">A Grade 2C recommendation is a very weak recommendation; other alternatives may be equally reasonable.</td>\n</tr>\n\n<tr>\n<td class=\"subtitle2_single\">Explanation:</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">A Grade 2 recommendation is a weak recommendation. It means \"this is our suggestion, but you may want to think about it.\" It is unlikely that you should follow the suggested approach in all your patients, and you might reasonably choose an alternative approach. For Grade 2 recommendations, benefits and risks may be finely balanced, or the benefits and risks may be uncertain. In deciding whether to follow a Grade 2 recommendation in an individual patient, you may want to think about your patient's values and preferences or about your patient's risk aversion.</td>\n</tr>\n\n<tr>\n<td class=\"indent1\">Grade C means the evidence comes from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.</td>\n</tr>\n\n</tbody>\n</table>\n</div>\n\n<div class=\"graphic_lgnd\"><strong>Recommendation grades</strong><br />\t\n1. Strong recommendation: Benefits clearly outweigh the risks and burdens (or vice versa) for most, if not all, patients<br />\n2. Weak recommendation: Benefits and risks closely balanced and/or uncertain<br /><br />\n<strong>Evidence grades</strong><br />\nA. High-quality evidence: Consistent evidence from randomized trials, or overwhelming evidence of some other form<br />\nB. Moderate-quality evidence: Evidence from randomized trials with important limitations, or very strong evidence of some other form<br />\nC. Low-quality evidence: Evidence from observational studies, unsystematic clinical observations, or from randomized trials with serious flaws<br /><br />\nFor a complete description of our grading system, please see the UpToDate editorial policy.</div>\n<div class=\"graphic_footnotes\"></div> \n<div class=\"graphic_reference\"></div>\n\n</div>\n</div>\n\n\n"];